Stockscreener 앱 받기
6.66
7.11%
-0.51
전일 마감가:
$7.17
열려 있는:
$7.12
하루 거래량:
6.69M
Relative Volume:
1.28
시가총액:
$1.40B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-37.00
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
-10.00%
1개월 성능:
-10.84%
6개월 성능:
-22.47%
1년 성능:
-5.67%
1일 변동 폭
$6.575
$7.17
1주일 범위
$6.575
$7.33
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.66 | 1.51B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Does BioCryst (BCRX) 2026 Revenue Guidance Reframe the ORLADEYO Growth Story for Investors? - simplywall.st
Stock Recap: What is The OLB Group Incs P E ratio telling us2025 Macro Impact & Smart Money Movement Alerts - baoquankhu1.vn
(BCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Aug Volume: Why BioCryst Pharmaceuticals Inc stock could outperform in 2025 - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc stock outperform growth indexes2025 Momentum Check & Reliable Momentum Entry Alerts - Bộ Nội Vụ
BioCryst stock holds steady as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com UK
Citizens reiterates Market Outperform rating on BioCryst Pharma stock By Investing.com - Investing.com Canada
BioCryst reports $563 million in ORLADEYO revenue for 2025 By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals (BCRX) Stock Analysis: A Rare Disease Innovator with 189% Upside Potential - DirectorsTalk Interviews
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - MarketBeat
Investment Report: Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zoneMarket Sentiment Review & Weekly Watchlist of Top Performers - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & AI Enhanced Trading Signals - Bộ Nội Vụ
BCRX: ORLADEYO growth, Astria acquisition, and pipeline advances drive rare disease expansion - TradingView — Track All Markets
BioCryst reports $563 million in ORLADEYO revenue for 2025 - Investing.com
BCRX Forecasts FY26 ORLADEYO Revenue in Range of $625M-$645M - GuruFocus
BCRX: ORLADEYO Sees Strong Revenue Growth in Q4 2025 - GuruFocus
(BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M - marketscreener.com
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - The Manila Times
Once-daily pill for HAE patients now brings in $601M a year - Stock Titan
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play - MSN
Published on: 2026-01-10 14:45:46 - Улправда
FDA approves seven NMEs in December - biocentury.com
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility - Sahm
BioCryst Pharmaceuticals, Inc.Common Stock (NQ: BCRX - FinancialContent
BioCryst to buy Astria Therapeutics for $13 per share (update) - MSN
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack - Investing.com Nigeria
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack By Investing.com - Investing.com South Africa
BioCryst Raises Price of Key ORLADEYO Treatment - TipRanks
BioCryst Pharmaceuticals Increases ORLADEYO® Price - TradingView — Track All Markets
Is BioCryst Pharmaceuticals Inc. stock oversold or undervalued2025 Trading Recap & AI Forecasted Entry and Exit Points - ulpravda.ru
How BioCryst Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - Улправда
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsGap Down & Free Verified High Yield Trade Plans - ulpravda.ru
CEO Moves: Will BioCryst Pharmaceuticals Inc. stock deliver long term returnsPortfolio Update Report & Expert Verified Movement Alerts - Улправда
HC Wainwright lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 from $30 - MSN
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Yahoo Finance
RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - The Malaysian Reserve
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Inves - GuruFocus
BioCryst reports inducement grants under Nasdaq listing rule - MSN
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
BioCryst Pharmaceuticals Q2 2025 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Liquidity Mapping Around (BCRX) Price Events - Stock Traders Daily
Will BioCryst Pharmaceuticals Inc. stock beat EPS estimatesRisk Management Strategies & Invest Smarter With Signals - bollywoodhelpline.com
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
Charlie Gayer to be BioCryst CEO effective January 1 - The Pharma Letter
BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says - marketscreener.com
Rice Hall James & Associates LLC Sells 179,891 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
1.45%
자본화:
|
볼륨(24시간):